Home Cart Sign in  
Chemical Structure| 377727-87-2 Chemical Structure| 377727-87-2
Chemical Structure| 377727-87-2
Product Citations

Alternative Products

Product Details of Preladenant

CAS No. :377727-87-2
Formula : C25H29N9O3
M.W : 503.56
SMILES Code : NC1=NC(N(CCN2CCN(C3=CC=C(OCCOC)C=C3)CC2)N=C4)=C4C5=NC(C6=CC=CO6)=NN15
Synonyms :
SCH-420814; MK-3814; Privadenant
MDL No. :MFCD17167056
InChI Key :DTYWJKSSUANMHD-UHFFFAOYSA-N
Pubchem ID :10117987

Safety of Preladenant

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Preladenant

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description Reference
Primary microglia 1 μM Preladenant prevented adenosine-induced process retraction in activated microglia PMC4408916
Primary microglia 1 μM Preladenant prevented adenosine-induced process retraction in activated microglia. PMC4408916

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
Mice Parkinson's disease model Perfusion 5 μM Continuous perfusion Restored microglial response to tissue injury PMC4072497
Mice LPS-induced neuroinflammation model Intraperitoneal injection 3 mg/kg Single injection, imaging after 1 hour Preladenant accelerated the microglial response to tissue damage PMC4408916
Mice LPS-induced neuroinflammation model Intraperitoneal injection 3 mg/kg Single injection, lasting 1 hour Preladenant accelerated the response of activated microglia to injury following systemic inflammation. PMC4408916

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00406029 Parkinson Disease ... More >> Movement Disorders Central Nervous System Diseases Neurodegenerative Diseases Brain Diseases Less << Phase 2 Completed - -
NCT01155466 Parkinson Disease Phase 3 Completed - -
NCT01215227 Parkinson Disease ... More >> Idiopathic Parkinson Disease Less << Phase 3 Terminated - -
NCT01155479 Parkinson Disease Phase 3 Terminated(Termininated for bu... More >>siness reasons) Less << - -
NCT00845000 Parkinson Disease Phase 1 Completed - -
NCT01155466 - Completed - -
NCT00845000 - Completed - -
NCT00406029 - Completed - -
NCT00693472 Akathisia, Drug-Induced ... More >> Antipsychotic Agents Movement Disorders Less << Phase 2 Terminated - -
NCT00693472 - Terminated - -
NCT01215227 - Terminated - -
NCT01155479 - Terminated(Termininated for bu... More >>siness reasons) Less << - -
NCT00537017 - Completed - -
NCT00686699 Akathisia, Drug-Induced ... More >> Dyskinesia, Drug-Induced Parkinsonian Disorders Less << Phase 2 Terminated(The study was termi... More >>nated after 9 participants completed due to lack of enrollment for 6 months.) Less << - -
NCT00686699 - Terminated(The study was termi... More >>nated after 9 participants completed due to lack of enrollment for 6 months.) Less << - -
NCT01294800 Parkinson's Disease Phase 2 Completed - -
NCT01294800 - Completed - -
NCT01227265 Parkinson Disease ... More >> Idiopathic Parkinson Disease Idiopathic Parkinson's Disease Less << Phase 3 Completed - -
NCT03099161 Neoplasm Phase 1 Terminated("The data did not s... More >>upport study endpoints") Less << - United States, Michigan ... More >> START Midwest ( Site 0001) Grand Rapids, Michigan, United States, 49546 Canada, Ontario Princess Margaret Hospital ( Site 0010) Toronto, Ontario, Canada, H9H 4M7 Canada, Quebec Jewish General Hospital ( Site 0011) Montreal, Quebec, Canada, H9H 4M7 Israel Rambam Health Care Campus ( Site 0020) Haifa, Israel Tel Aviv Sourasky Medical Center ( Site 0021) Tel Aviv, Israel Less <<
NCT01323855 Parkinson Disease PHASE1 COMPLETED 2011-11-29 -
NCT01323855 Parkinson Disease PHASE1 COMPLETED 2011-11-29 -
NCT00537017 Parkinson Disease ... More >> Neurodegenerative Diseases Central Nervous System Diseases Movement Disorders Brain Diseases Less << Phase 2 Completed - -
NCT01465412 Chronic Hepatic Impairment PHASE1 COMPLETED 2012-06-14 -
NCT01227265 - Completed - -
NCT01465412 Chronic Hepatic Impairment PHASE1 COMPLETED 2012-06-14 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.99mL

0.40mL

0.20mL

9.93mL

1.99mL

0.99mL

19.86mL

3.97mL

1.99mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories